Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2025 Aug 1;14(4):673-675.
doi: 10.21037/hbsn-2025-315. Epub 2025 Jul 24.

Balancing efficacy and tolerability in metastatic pancreatic cancer: lessons from the ALPACA trial

Tadahisa Inoue  1 , Akihisa Kato  2 , Michihiro Yoshida  2 , Tomoya Kitada  1 , Rena Kitano  1 , Itaru Naitoh  3
Affiliations
Editorial

Balancing efficacy and tolerability in metastatic pancreatic cancer: lessons from the ALPACA trial

Tadahisa Inoue et al. Hepatobiliary Surg Nutr. .
No abstract available

Keywords: Nab-paclitaxel; dose-reduction strategy; gemcitabine; maintenance chemotherapy; metastatic pancreatic cancer.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://hbsn.amegroups.com/article/view/10.21037/hbsn-2025-315/coif). The authors have no conflicts of interest to declare.

Comment on

References

    1. Siegel RL, Miller KD, Wagle NS, et al. Cancer statistics, 2023. CA Cancer J Clin 2023;73:17-48. 10.3322/caac.21763 - DOI - PubMed
    1. Von Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 2013;369:1691-703. 10.1056/NEJMoa1304369 - DOI - PMC - PubMed
    1. Goldstein D, El-Maraghi RH, Hammel P, et al. nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: long-term survival from a phase III trial. J Natl Cancer Inst 2015;107:dju413. 10.1093/jnci/dju413 - DOI - PubMed
    1. Dorman K, Boeck S, Caca K, et al. Alternating gemcitabine plus nab-paclitaxel and gemcitabine alone versus continuous gemcitabine plus nab-paclitaxel after induction treatment of metastatic pancreatic cancer (ALPACA): a multicentre, randomised, open-label, phase 2 trial. Lancet Gastroenterol Hepatol 2024;9:935-43. 10.1016/S2468-1253(24)00197-3 - DOI - PubMed
    1. Scheithauer W, Ramanathan RK, Moore M, et al. Dose modification and efficacy of nab-paclitaxel plus gemcitabine vs. gemcitabine for patients with metastatic pancreatic cancer: phase III MPACT trial. J Gastrointest Oncol 2016;7:469-78. 10.21037/jgo.2016.01.03 - DOI - PMC - PubMed

LinkOut - more resources